Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
International Stem Cell Corp. Stock Analysis ISCO
United States Health Care Nano Cap International Stem Cell Corp. operates as a research and development company for the therapeutic market. The company is headquartered in San Diego, California and currently employs 33 full-time employees. The company went IPO on 2006-09-25. The firm is primarily a research and development company for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The firm's products are based on human cell culture and types of pluripotent stem cells and hpSCs. The firm's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.
Read More International Stem Cell Corp (ISCO) Chart
Key Statistics of International Stem Cell Corp (ISCO)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.20Volume
1400.00P/E Ratio (TTM)
-52 Week Range
Market Cap
1.36MAvg. Volume
1330.63Dividend Yield
-Financial Metrics & Statements of International Stem Cell Corp (ISCO)
FAQ's for International Stem Cell Corp (ISCO)
- According to Musaffa’s Shariah screening methodology, International Stem Cell Corp (ISCO) is currently classified as NOT COVERED as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes International Stem Cell Corp using these criteria to determine its compliance status.
- Muslim investors may consider investing in International Stem Cell Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of International Stem Cell Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of International Stem Cell Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of International Stem Cell Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.